Omeprazole Zentiva

Omeprazole, the active ingredient in Omeprazole Zentiva, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazole Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Zentiva belongs to the proton pump inhibitor class and is indicated for acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success when used with antibiotics.

Adverse reactions to Omeprazole Zentiva are generally mild to moderate and vary with individual sensitivity.

Common Side Effects: - Headache - Diarrhoea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated colitis - Low magnesium levels (hypomagnesemia) - Acute interstitial nephritis - Stevens‑Johnson syndrome - Bone fracture risk with long‑term use

When prescribing Omeprazole Zentiva, clinicians should consider several safety aspects. - Assess patient history for liver disease: dose adjustment may be needed. - Evaluate renal function: monitor for electrolyte disturbances. - Review concomitant use of drugs that require gastric acidity for absorption. - Use caution in patients with known hypersensitivity to benzimidazoles. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Omeprazole can interact with a range of medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased antiviral absorption. - Methotrexate (high‑dose): increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential INR elevation. - Digoxin: altered serum concentrations. - Phenytoin: reduced plasma levels. - Fluoroquinolone antibiotics (e.g., ciprofloxacin): decreased absorption.